- Home
- GH vs MAN Comparison
GH vs MAN Comparison
Compare GH & MAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- MAN
- Stock Information
- Founded
- GH 2011
- MAN 1948
- Country
- GH United States
- MAN United States
- Employees
- GH N/A
- MAN N/A
- Industry
- GH Medical Specialities
- MAN Professional Services
- Sector
- GH Health Care
- MAN Consumer Discretionary
- Exchange
- GH Nasdaq
- MAN Nasdaq
- Market Cap
- GH 2.7B
- MAN 3.1B
- IPO Year
- GH 2018
- MAN 1988
- Fundamental
- Price
- GH $30.98
- MAN $60.82
- Analyst Decision
- GH Strong Buy
- MAN Hold
- Analyst Count
- GH 15
- MAN 6
- Target Price
- GH $39.93
- MAN $76.60
- AVG Volume (30 Days)
- GH 2.2M
- MAN 558.7K
- Earning Date
- GH 11-06-2024
- MAN 10-17-2024
- Dividend Yield
- GH N/A
- MAN 4.97%
- EPS Growth
- GH N/A
- MAN N/A
- EPS
- GH N/A
- MAN 0.78
- Revenue
- GH $692,256,000.00
- MAN $18,084,700,000.00
- Revenue This Year
- GH $31.00
- MAN N/A
- Revenue Next Year
- GH $17.55
- MAN $1.14
- P/E Ratio
- GH N/A
- MAN $77.44
- Revenue Growth
- GH 29.20
- MAN N/A
- 52 Week Low
- GH $15.81
- MAN $59.35
- 52 Week High
- GH $37.04
- MAN $80.25
- Technical
- Relative Strength Index (RSI)
- GH 70.13
- MAN 35.27
- Support Level
- GH $28.45
- MAN $59.35
- Resistance Level
- GH $32.26
- MAN $65.45
- Average True Range (ATR)
- GH 1.70
- MAN 1.19
- MACD
- GH 0.39
- MAN -0.10
- Stochastic Oscillator
- GH 75.19
- MAN 20.56
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that includes Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives maximum of the company's revenue. The company derives maximum geographical revenue from Southern European region.